» Articles » PMID: 17698745

Sepsis and the Heart

Overview
Journal Circulation
Date 2007 Aug 19
PMID 17698745
Citations 240
Authors
Affiliations
Soon will be listed here.
Abstract

Sepsis is generally viewed as a disease aggravated by an inappropriate immune response encountered in the afflicted individual. As an important organ system frequently compromised by sepsis and always affected by septic shock, the cardiovascular system and its dysfunction during sepsis have been studied in clinical and basic research for more than 5 decades. Although a number of mediators and pathways have been shown to be associated with myocardial depression in sepsis, the precise cause remains unclear to date. There is currently no evidence supporting global ischemia as an underlying cause of myocardial dysfunction in sepsis; however, in septic patients with coexistent and possibly undiagnosed coronary artery disease, regional myocardial ischemia or infarction secondary to coronary artery disease may certainly occur. A circulating myocardial depressant factor in septic shock has long been proposed, and potential candidates for a myocardial depressant factor include cytokines, prostanoids, and nitric oxide, among others. Endothelial activation and induction of the coagulatory system also contribute to the pathophysiology in sepsis. Prompt and adequate antibiotic therapy accompanied by surgical removal of the infectious focus, if indicated and feasible, is the mainstay and also the only strictly causal line of therapy. In the presence of severe sepsis and septic shock, supportive treatment in addition to causal therapy is mandatory. The purpose of this review is to delineate some characteristics of septic myocardial dysfunction, to assess the most commonly cited and reported underlying mechanisms of cardiac dysfunction in sepsis, and to briefly outline current therapeutic strategies and possible future approaches.

Citing Articles

MicroRNAs as regulators of cardiac dysfunction in sepsis: pathogenesis and diagnostic potential.

Liu Z, Li F, Li N, Chen Y, Chen Z Front Cardiovasc Med. 2025; 12:1517323.

PMID: 40041174 PMC: 11876399. DOI: 10.3389/fcvm.2025.1517323.


Beyond the Beat: A Multifaceted Review of Atrial Fibrillation in Sepsis: Risk Factors, Management Strategies, and Economic Impact.

Ho W, Umais M, Bai M, Dang N, Kumari K, Izhar S Cardiol Res. 2025; 16(1):1-14.

PMID: 39897439 PMC: 11779681. DOI: 10.14740/cr1723.


Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.

Windsor C, Joseph A, Pons S, Mokart D, Pene F, Kouatchet A J Intensive Med. 2025; 5(1):64-69.

PMID: 39872834 PMC: 11763860. DOI: 10.1016/j.jointm.2024.07.005.


Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy.

Liu P, Yu X, Pan Q, Ren J, Han Y, Zhang K Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861106 PMC: 11768530. DOI: 10.3390/ph18010043.


The role of programmed cell death in organ dysfunction induced by opportunistic pathogens.

Wang Y, Weng L, Wu X, Du B Crit Care. 2025; 29(1):43.

PMID: 39856779 PMC: 11761187. DOI: 10.1186/s13054-025-05278-x.